Avibactam confers susceptibility to a large proportion of ceftazidime-resistantPseudomonas aeruginosaisolates recovered from cystic fibrosis patients

Pseudomonas aeruginosa infection in cystic fibrosis lung disease and new perspectives of treatment: a review

(2013) M. C. Gaspar et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Diversity of  -lactam resistance mechanisms in cystic fibrosis isolates of Pseudomonas aeruginosa: a French multicentre study

(2013) C. Llanes et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Kinetics of Avibactam Inhibition against Class A, C, and D β-Lactamases

(2013) David E. Ehmann et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Avibactam reverts the ceftazidime MIC90 of European Gram-negative bacterial clinical isolates to the epidemiological cut-off value

(2013) Robert K. Flamm et al.   JOURNAL OF CHEMOTHERAPY

Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: V. Aminoglycosides

(2013) David C. Young et al.   PEDIATRIC PULMONOLOGY

In Vitro Activity of Ceftazidime Combined with NXL104 versus Pseudomonas aeruginosa Isolates Obtained from Patients in Canadian Hospitals (CANWARD 2009 Study)

(2011) A. Walkty et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitro activity of ceftazidime+NXL104 against Pseudomonas aeruginosa and other non-fermenters

(2010) S. Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY